Chance favors the prepared mind - From serendipity to rational drug design

Journal of Receptor and Signal Transduction Research

Volumn 19, Issue 1-4, 1999, Pages 15-39

  Kubinyi, Hugo ^a  

^a BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE; ACETYLSALICYLIC ACID; AMINOGLUTETHIMIDE; AMPHETAMINE; CAPTOPRIL; CHLORAL HYDRATE; CISPLATIN; CLONIDINE; CROMOGLYCATE DISODIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISULFIRAM; DORZOLAMIDE; ENZYME INHIBITOR; ETHER; ETOMIDATE; GUANETHIDINE; HEPARIN; IMIPRAMINE; INDINAVIR; INTEGRIN RECEPTOR; IPRONIAZID; ISONIAZID; LEVAMISOLE; LIGAND; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; ZANAMIVIR;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DESIGN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN STRUCTURE; REACTION ANALYSIS; RESEARCH; SCIENCE; STRUCTURE ANALYSIS;

EID: 0033025637     PISSN: 10799893     EISSN: None     Source Type: Journal    
DOI: 10.3109/10799899909036635     Document Type: Conference Paper

References (70)

1. Roberts, R.M. Serendipity. Accidental discoveries in science. John Wiley & Sons, New York, 1989.
2. Lewis, S.L., Ed. Horace Walpole's Correspondence. 31 Vols., Yale University Press, New Haven, 1937 ff.
3. Remer, T.G. Serendipity and the three princes. From the Peregrinaggio of 1557. University of Oklahoma Press, Norman, 1965. Translated from the book Peregrinaggio di tre giovani, figliuoli del re di Serendippo; tradotto dalla lingua persiana in lingua italiana do M. Christoforo Armeno. Venice, Michele Tramezzino, 1557.
4. Remer, T.G. Serendipity and the three princes. From the Peregrinaggio of 1557. University of Oklahoma Press, Norman, 1965. Translated from the book Peregrinaggio di tre giovani, figliuoli del re di Serendippo; tradotto dalla lingua persiana in lingua italiana do M. Christoforo Armeno. Venice, Michele Tramezzino, 1557.
5. Sneader W. Drug prototypes and their exploitation, John Wiley & Sons, Chichester, 1996.
6. Burger, A. A guide to the chemical basis of drug design. John Wiley & Sons, New York, 1983.
7. de Stevens, G. Serendipity and structured research in drug discovery, Progr. Drug Res. 30, 189-203, 1986.
8. Restak, R.M. Receptors, Bantam Books, New York, 1994.
9. Böhm, H.-J.; Klebe, G. and Kubinyi, H. Wirkstoffdesign. Spektrum Akademischer Verlag, Heidelberg, 1996.
10. Sternbach, L.H. The benzodiazepine story. Progr. Drug Res. 22, 229-266, 1978.
11. Wolff, M.E., Ed. Burger's medicinal chemistry and drug discovery. Volume 1: Principles and practice. John Wiley & Sons, New York, 1995.
12. Sternweis, P.C. and Gilman, A. G. Aluminum: a requirement for activation of the regulatory component of adenylate cyclase by fluoride. Proc. Natl. Acad. Sci. USA 79, 4888-4891, 1982.
13. -. Nature 372, 276-279, 1994.
14. Goodford, P.J. Drug design by the method of receptor fit. J. Med. Chem. 27, 557-564, 1984.
15. Ganellin, C.R. and Roberts, S.M. Medicinal chemistry. The role of organic chemistry in drug research. Second Edition, Academic Press, London, 1993.
16. Greer, J.; Erickson, J.W.; Baldwin, J.J. and Varney, M.D. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J. Med. Chem. 37, 1035-1054, 1994.
17. Vacca, J.P. and Condra, J.H. Clinically effective HIV-1 protease inhibitors. Drug Discovery today 2, 6-18, 1997.
18. von Itzstein, M.; Wu, W.Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Phan, T.V.; Smythe, M.L; White, H.F.; Oliver, S.W.; Colman, P.M.; Varghese, J.N.; Ryan, D.M.; Woods, J.M.; Bethell, R.C.; Hotham, V.J.; Cameron, J.M. and Penn, C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418-423, 1993.
19. von Itzstein, M.; Dyason, J.C.; Oliver, S.W.; White, H.F.; Wu, W.Y.; Kok, G.B. and Pegg, M.S. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J. Med. Chem. 39, 388-391, 1996.
20. Chand, P.; Babu, Y.S.; Bantia, S.; Chu, N.; Cole, L.B.; Kotian, P.L.; Laver, W.G.; Montgomery, J.A.; Pathak, V.P.; Petty, S.L.; Shrout, D.P.; Walsh, D.A. and Walsh, G.M. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J. Med. Chem. 40, 4030-4052, 1997.
21. Kim. C.U.; Lew, W.; Williams, M.A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M.S.; Mendel, D.B.; Tai, C.Y.; Laver, W.G. and Stevens, R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119:681-690, 1997.
22. Beddell, C.R., Ed. The design of drugs to macromolecular targets. John Wiley & Sons, Chichester, 1992.
23. Wermuth, C.G., Ed. The practice of medicinal chemistry. Academic Press, London, 1996.
24. Bohacek, R.S.; McMartin, C. and Guida, W.C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3-50, 1996.
25. Babine, R.E. and Bender, S.L. Molecular recognition of proteinligand complexes: applications to drug design. Chem. Rev. 97, 1359-1472, 1997.
26. Veerapandian, P., Ed. Structure-based drug design. Marcel Dekker, Inc., New York, 1997.
27. Gubernator, K. and Böhm, H.-J., Eds. Structure-based drug design. Wiley-VCH, Weinheim, 1998.
28. Evans, B.E.; Bock, M.G.; Rittle, K.E.; DiPardo, R.M.; Whitter, W.L.; Veber, D.F.; Anderson, P.S. and Freidinger, R.M. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc. Natl. Acad. Sci. USA 83, 4918-4922, 1986.
29. Samanen, J. GPIIb/IIIa antagonists. Annu. Rep. Med. Chem. 31, 91-100, 1996.
30. Engleman, V.W.; Kellogg, M.S. and Rogers, T.E. Cell adhesion integrins as pharmaceutical targets. Annu. Rep. Med. Chem. 31, 191-200, 1996.
31. Samanen, J.M.; Ali, F.E.; Barton, L.S.; Bondinell, W.E.; Burgess, J.L.; Callahan, J.F.; Calvo, R.R.; Chen, W.; Chen, L.; Erhard, K.; Feuerstein, G.; Heys, R.; Hwang, S.M.; Jakas, D.R.; Keenan, R.M.; Ku, T.W.; Kwon, C.; Lee, C.P.; Miller, W.H.; Newlander, K.A.; Nichols, A.; Parker, M.; Peishoff, C.E.; Rhodes, G.; Ross, S.; Shu, A.; Simpson, R.; Takata, D.; Yellin, T.O.; Uzsinskas, I.; Venslavsky, J.W.; Yuan, C.K. and Huffman, W.F. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists. J. Med. Chem. 39, 4867-4870, 1996.
32. Keenan, R.M.; Miller, W.H.; Kwon, C.; Ali, F.E.; Callahan, J.F.; Calvo, R.R.; Hwang, S.M.; Kopple, K.D.; Peishoff, C.E.; Samanen, J.M.; Wong, A.S.; Yuan, C.K. and Huffman, W.F. Discovery of potent nonpeptide vitronectin receptor (αvβ3) antagonists. J. Med. Chem. 40, 2289-2292, 1997.
33. Gulliver's Travels, published anonymously, Motte, London, 1726; Swift, J. Gulliver's Travels. Part III. A voyage to Laputa, Balnibarbi, Glubbdubdrib, Luggnagg and Japan, Chapter 5. Penguin Classics, Penguin Books Ltd., London, 1985, p. 223-231.
34. Gulliver's Travels, published anonymously, Motte, London, 1726; Swift, J. Gulliver's Travels. Part III. A voyage to Laputa, Balnibarbi, Glubbdubdrib, Luggnagg and Japan, Chapter 5. Penguin Classics, Penguin Books Ltd., London, 1985, p. 223-231.
35. Dolle, R.E. Discovery of enzyme inhibitors through combinatorial chemistry. Molecular Diversity 2, 223-236, 1996.
36. Cowley, P.M. and Rees, D.C. Applications of solid-phase synthesis to drug discovery. Curr. Med. Chem. 4, 211-227, 1997.
37. Bone, R. and Salemme, F.R. The integration of structure-based design and directed combinatorial chemistry for new pharmaceutical discovery. In Structure-based drug design, Veerapandian, P., Ed. Marcel Dekker, New York, 1997, p. 525-539.
38. Myers, P.L. Will combinatorial chemistry deliver real medicines? Curr. Opin. Biotechnol. 8, 701-707, 1997.
39. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P. and Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534, 1996.
40. Hajduk, P.J.; Meadows, R.P. and Fesik, S.W. Discovering high-affinity ligands for proteins. Science 278, 497-499, 1997.
41. Hajduk, P.J.; Sheppard, G.; Nettesheim, D.G.; Olejniczak, E.T.; Shuker, S.B.; Meadows, R.P.; Steinman, D.H.; Carrera Jr., G.M.; Marcotte, P.A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T.F.; Morgan, D.W.; Davidsen, S.K.; Summers, J.B. and Fesik, S.W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 119, 5818-5827, 1997.
42. Müller, K., Ed. De novo design. Persp. Drug Discov. Design 3, 1-209, 1995.
43. Höltje, H.D. and Folkers, G. Molecular modeling. Basic principles and applications. VCH, Weinheim, 1996.
44. Bamborough, P. and Cohen, F.E. Modeling protein-ligand complexes. Curr. Opin. Struct. Biol. 6, 236-241, 1996.
45. Böhm, H.-J. Computational tools for structure-based ligand design. Prog. Biophys. Molec. Biol. 66, 197-210, 1996.
46. Böhm, H.-J. Current computational tools for de novo ligand design. Curr. Opin. Biotechnol. 7, 433-436, 1996.
47. Lengauer, T. and Rarey, M. Computational methods for biomolecular docking. Curr. Opin. Struct. Biol. 6, 402-406, 1996.
48. Marrone, T.J.; Briggs, J.M. and McCammon, J.A. Structure-based drug design: computational advances. Annu. Rev. Pharmacol. Toxicol. 37, 71-90, 1997.
49. Parrill, A. Recent advances in computer-aided drug design methods. Exp. Opin. Ther. Patents 7, 937-945, 1997.
50. Lemmen, C. and Lengauer, T. Time-efficient flexible superposition of medium-sized molecules. J. Comput.-Aided Mol. Design 11, 357-368, 1997. See also http://cartan.gmd.de/flex-bin/FlexS.
51. Rarey, M.; Kramer, B.; Lengauer, T. and Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261, 470-489, 1996. See also http://cartan.gmd.de/flex-bin/FlexX.
52. Makino, S. and Kuntz, I.D. Automated flexible ligand docking method and its application for database search. J. Comput. Chem. 18, 1812-1825, 1997.
53. Westhead, D.R.; Clark, D.E. and Murray, C.W. A comparison of heuristic search algorithms for molecular docking. J. Comput.-Aided Mol. Design 11, 203-228, 1997.
54. Dixon, J.S. Evaluation of the CASP2 docking section. Proteins 27 Suppl. 1, 198-204, 1997, and following articles in this special issue on the "Second Meeting on the Critical Assessment of Techniques for Protein Structure Prediction" (CASP2), Asilomar, CA, USA, December 13-16, 1996.
55. Dixon, J.S. Evaluation of the CASP2 docking section. Proteins 27 Suppl. 1, 198-204, 1997, and following articles in this special issue on the "Second Meeting on the Critical Assessment of Techniques for Protein Structure Prediction" (CASP2), Asilomar, CA, USA, December 13-16, 1996.
56. Böhm, H.-J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Design 6, 61-78, 1992.
57. Böhm, H.-J. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J. Comput.-Aided Mol. Design 6, 593-606, 1992.
58. Böhm, H.-J. Ligand design. In: 3D QSAR in drug design. Theory, methods and applications. Kubinyi, H., Ed. ESCOM Science Publishers B.V., Leiden, 1993, p. 386-405.
59. Böhm, H.-J. Towards the automatic design of synthetically accessible protein ligands: peptides, amides and peptidomimetics. J. Comput.-Aided Mol. Design 10, 265-272, 1996.
60. th European symposium on quantitative structure-activity relationships, Lausanne, 1996), van de Waterbeemd, H.; Testa, B. and Folkers, G., Eds. Verlag Helvetica Chimica Acta and VCH, Basel and Weinheim, 1997, p. 123-133.
61. Caflisch, A. and Karplus, M. Computational combinatorial chemistry for de novo ligand design: review and assessment. Persp. Drug Discov. Design 3, 51-84, 1995.
62. Caflisch, A. and Ehrhardt, C. Structure-based combinatorial ligand design. In Structure-based drug design, Veerapandian, P., Ed. Marcel Dekker, New York, 1997, p. 541-558.
63. Hubbard, R.E. Can drugs be designed? Curr. Opin. Biotechnol. 8, 696-700, 1997.
64. Graul, A.I. The year's new drugs. Drug News Perspect. 11, 15-32, 1998.
65. Kubinyi, H.; Folkers, G. and Martin, Y.C., Eds. 3D QSAR in drug design. Volume 2. Ligand-protein interactions and molecular similarity, Kluwer Academic Publishers, Dordrecht, 1998.
66. Mattos, C. and Ringe, D. Multiple binding modes. In: 3D-QSAR in drug design. Theory, methods and applications. Kubinyi, H., Ed. ESCOM Science Publishers B.V., Leiden, 1993, p. 226-254.
67. Meyer, E.F.; Botos, I.; Scapozza, L. and Zhang, D. Backward binding and other structural surprises. Persp. Drug. Discov. Design 3, 168-195, 1995.
68. Böhm, H.-J. and Klebe, G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew. Chem. Int. Ed. Engl. 35, 2589-2614, 1996.
69. Kubinyi, H.: Similarity and dissimilarity: a medicinal chemist's view. In: 3D QSAR in drug design. Ligand-protein interactions and molecular similarity. Kubinyi, H.; Folkers, G. and Martin, Y. C., Eds. Kluwer Academic Publishers, Dordrecht, 1998, p. 225-252.
70. Zinkernagel, R.M. Lecture "Immunität gegen Viren", presented at the Symposium "Pharmazie. Die Wissenschaft vom Arzneimittel" of the German and Swiss Pharmaceutical Societies, Zurich, Switzerland, October 02-05, 1997.